to drug development. Deep Genomics is at the forefront.
Creating A New Universe Of
Genetic Medicines
Revolutions in AI, biology and automation are enabling a new approach
to drug development. Deep Genomics is at the forefront.
to drug development. Deep Genomics is at the forefront.
News

“Deep Genomics, founded in 2015, is at the forefront of efforts by big companies, startups and ...”
October 19, 2018

“For the first time in history, our ability to collect data on our biology has outpaced our ability to...”
April 1, 2019

“The basic fact is no human or group of humans will ever understand how the genome works”
August 28, 2017

“The next blockbuster drug could be developed with help from machine learning techniques”
May 3, 2017
Updates
Learn about the latest developments at Deep Genomics
Amanda Kay Appointed Chief Business Officer of Deep Genomics, Tasked with Overseeing Expansion of Partnership Strategy
November 5, 2020
DEEP GENOMICS RAISES $40 MILLION IN SERIES B FINANCING
January 7, 2020
DEEP GENOMICS PLANS FOR CLINICAL INNOVATION, APPOINTS PETER BARTON HUTT AS STRATEGIC ADVISOR
June 25, 2019
Deep Genomics is proud to announce that Peter Barton Hutt, Senior Counsel at
Covington & Burling and former Chief Counsel of the U.S. Food and Drug Administration,
has joined the company as a Strategic Advisor.
© 2021 DEEP GENOMICS. ALL RIGHTS RESERVED.